Adenosine Deaminase Activity in Type 2 Diabetes Mellitus

Abstract

BACKGROUND Altered blood levels of adenosine deaminase may help in predicting immunological dysfunction in diabetic individuals. But very few studies exist on ADA activity in type 2 diabetes mellitus. Aim of this study is to compare serum adenosine deaminase activity in type 2 diabetic patients with non-diabetic control. MATERIALS AND METHODS A comparative study design was used in data collection process. The study was conducted in 40 type 2 diabetes mellitus patients attending diabetic clinic or admitted in the medicine ward for metabolic control of diabetes in medical college, Calicut from January 2011 to January 2012. The adenosine deaminase (ADA) level in the serum is measured by endpoint method in these patients. The results were expressed as mean and standard deviation. The statistical significance of the differences between the values was assessed by ANOVA. RESULTS Among 40 diabetic patients, mean ADA level in the serum is 38.56, SD±6.72 (min 30, max 53). Mean ADA level in the serum in the control group is 22.04±4.625 (min 13, max 29). CONCLUSION ADA level in the serum is found to be increased indicating its role as an important immunoenzyme marker in the aetiopathology of type 2 diabetes mellitus.

Estimation of Nitric Oxide, Malondialdehyde, and Adenosine Deaminase in Serum of Hypertensive Patients and Normotensive Individuals in Erbil City

“…ADA appears to be an essential enzyme for modulating the bioactivity of insulin. The rise in plasma ADA activity is correlated with obesity, insulin resistance, abnormal lipid profile, and hypertension [17,18,19]. This study tried to determine variations in the levels of plasma nitric oxide (NO), malondialdehyde (MDA) as an indication of lipid peroxidation, and adenosine deaminase (ADA) in healthy control and patients with hypertension, to point out the alterations in their levels and to find whether correlation exists within each of these variables.…”